Dalton Pharma Services has entered a drug development and manufacturing services agreement with Cerium Pharmaceuticals, Inc., an emerging biopharma company focused on rare diseases based in Gaithersburg, MD.
 
Dalton will provide formulation development, cGMP liquid filling, analytical method validation, quality control release testing and ICH stability services to support of Cerium’s drug development program.
 
“Our expert capabilities in formulation development and sterile fill/finish of APIs combined with our strength in cGMP API manufacturing has led to the signing of this important drug development and manufacturing agreement,” said Peter Pekos, president and chief executive officer. “We are excited to have this opportunity and look forward to participating in Cerium’s drug development program, which has great promise for providing a therapy for a major unmet medical need.”
 
Gregg Lapointe, chief executive officer of Cerium said, “Dalton is an excellent fit for our needs, and we are delighted to be partnering with a company whose client focus and commitment to quality match our own.  Cerium will benefit greatly from having Dalton’s facilities, experience, technical expertise and array of integrated services to move our drug from R&D to cGMP manufacturing.”